Voyager's VY1706 Delivers 75% Tau Reduction and Clean Safety in Six-Month Primate Study
VYGR sits 23% above its 52-week low of $2.884.
Summary
Voyager's VY1706 achieved up to 75% tau reduction with a clean safety profile in a six-month primate study, de-risking the Alzheimer's gene therapy ahead of clinical trials starting later this year.
Key Events · Product Development and Regulatory · VYGR
-
Six-Month GLP Data Presented
VY1706 showed up to 75% tau protein reduction in non-human primates with no adverse CNS, DRG, or liver findings at the highest dose of 5e13 vg/kg.
-
ALPL Receptor Mechanism Identified
The ALPL receptor was shown to mediate VY1706 blood-brain barrier transport, supporting cross-species translatability and a novel delivery mechanism.
-
Clinical Trial on Track for H2 2026
Following June 2026 IND clearance, Voyager plans to begin dosing in a multi-site, dose-escalation trial in Alzheimer's patients in the second half of 2026.
-
Program De-Risking Ahead of Key Catalyst
The clean safety and durable efficacy data significantly reduce development risk for the lead asset, a major value driver for the company.
Analysis · VYGR · Life Sciences
At AAIC, Voyager presented six-month GLP toxicology data for its Alzheimer's gene therapy VY1706, demonstrating up to 75% tau protein reduction in non-human primates with no adverse CNS or liver findings at the highest dose. The identification of the ALPL receptor as the mediator of blood-brain barrier transport strengthens the mechanistic rationale and cross-species translatability. This data significantly de-risks the program ahead of the planned first-in-human dosing in the second half of 2026, following June's IND clearance. The clean safety profile and durable target engagement position VY1706 as a potentially best-in-class tau-targeting gene therapy, a major value driver for a $208M market cap company with cash runway into 2028.
At the time of this filing, VYGR was trading at $3.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.8M. The 52-week trading range was $2.88 to $5.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.